Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08
Emergent BioSolutions (NYSE:EBS) has announced that its Compensation Committee has approved an equity award for a new employee under its 2023 Inducement Plan. The award, granted on March 15, 2025, consists of restricted stock units and stock options totaling 72,882 shares of Emergent common stock. This equity grant was made in accordance with the NYSE Listing Rule 303A.08 employment inducement award exception. The awarded shares will fully vest on March 15, 2026, contingent upon the employee's continued service through the vesting date.
Emergent BioSolutions (NYSE:EBS) ha annunciato che il suo Comitato per la Compensazione ha approvato un premio azionario per un nuovo dipendente nell'ambito del suo Piano di Induzione 2023. Il premio, concesso il 15 marzo 2025, consiste in unità di azioni vincolate e opzioni su azioni per un totale di 72.882 azioni ordinarie di Emergent. Questa concessione azionaria è stata effettuata in conformità con l'eccezione del premio di induzione all'impiego secondo la Regola di quotazione NYSE 303A.08. Le azioni assegnate si acquisiranno completamente il 15 marzo 2026, subordinatamente alla continuazione del servizio del dipendente fino alla data di acquisizione.
Emergent BioSolutions (NYSE:EBS) ha anunciado que su Comité de Compensación ha aprobado un premio en acciones para un nuevo empleado bajo su Plan de Inducción 2023. El premio, otorgado el 15 de marzo de 2025, consiste en unidades de acciones restringidas y opciones sobre acciones que suman un total de 72,882 acciones ordinarias de Emergent. Esta concesión de acciones se realizó de acuerdo con la excepción del premio de inducción laboral según la Regla de Cotización 303A.08 de la NYSE. Las acciones otorgadas se consolidarán completamente el 15 de marzo de 2026, sujeto a la continuidad del servicio del empleado hasta la fecha de consolidación.
Emergent BioSolutions (NYSE:EBS)는 보상 위원회가 2023 유인 계획에 따라 새로운 직원에게 주식 보상을 승인했다고 발표했습니다. 이 보상은 2025년 3월 15일에 부여되었으며, 총 72,882주의 Emergent 보통주로 구성된 제한 주식 단위 및 주식 옵션으로 이루어져 있습니다. 이 주식 보상은 NYSE 상장 규칙 303A.08의 고용 유인 보상 예외에 따라 이루어졌습니다. 수여된 주식은 2026년 3월 15일에 완전히 귀속되며, 이는 직원이 귀속 날짜까지 계속 근무해야 합니다.
Emergent BioSolutions (NYSE:EBS) a annoncé que son Comité de Rémunération a approuvé une attribution d'actions pour un nouvel employé dans le cadre de son Plan d'Induction 2023. L'attribution, accordée le 15 mars 2025, se compose d'unités d'actions restreintes et d'options d'achat d'actions totalisant 72 882 actions ordinaires d'Emergent. Cette attribution d'actions a été effectuée conformément à l'exception d'attribution d'incitation à l'emploi selon la Règle de cotation NYSE 303A.08. Les actions attribuées deviendront entièrement acquises le 15 mars 2026, sous réserve que l'employé continue de travailler jusqu'à la date d'acquisition.
Emergent BioSolutions (NYSE:EBS) hat bekannt gegeben, dass der Vergütungsausschuss eine Aktienauszeichnung für einen neuen Mitarbeiter im Rahmen seines Anreizplans 2023 genehmigt hat. Die Auszeichnung, die am 15. März 2025 gewährt wurde, besteht aus eingeschränkten Aktieneinheiten und Aktienoptionen, die insgesamt 72.882 Aktien des Stammkapitals von Emergent umfassen. Diese Aktienvergabe erfolgte gemäß der Ausnahme für Anreizvergaben nach der NYSE-Listing-Regel 303A.08. Die zugewiesenen Aktien werden am 15. März 2026 vollständig unverfallbar, vorausgesetzt, der Mitarbeiter bleibt bis zum Verfallstag im Dienst.
- None.
- None.
GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a leading public health company that delivers protective and life-saving solutions to communities across the world, today announced that its Compensation Committee has granted an equity award to a newly hired employee under its 2023 Inducement Plan (the "Inducement Plan").
The employee will receive an award of restricted stock units and stock options representing 72,882 shares of Emergent common stock (the “Equity Award”) as of March 15, 2025 in reliance on the employment inducement award exception to New York Stock Exchange Listing Rule 303A.08. The Equity Award will be fully vested on March 15, 2026, subject to the employee’s continuous service through the vesting date.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
How many shares were granted in Emergent BioSolutions (EBS) new employee equity award?
When will the EBS employee equity award vest?
What is the purpose of Emergent BioSolutions' 2023 Inducement Plan?
Under which NYSE rule was the EBS equity award granted?
